[{"title": "Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire", "description": "<a href=\"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQa3lzYWVYc2hOOTRJazNJMmpINUQwcmZ5NlRXY2xpbjJHR3JMVl8wRndfWVpIT2lpbHhlN2pzMTZVN05QZDV2SDZOcnVpbHByYWRhZFE4WVpKYWF1S0pZMkVFSFZQMnpaU3JIU3BVLWxsZEt6TlpqUVd0Y0hna2l6c2tUYkJFSHpfMGZRekNlbVQ2c0V1NGNEQTFJbl9SOFFhQU5ST2NqRG9zSFd1MWNTUlJ0SWFwUmtuaUY0c09Bd2hEZVZwcnFZN1FYMU1uaHNZUnJMaGlXaGM3UGxFNHFMRlFkb1hzakxSOWMwdg?oc=5\" target=\"_blank\">Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GlobeNewswire</font>", "publishedAt": "Wed, 13 Aug 2025 12:07:03 GMT"}, {"title": "Ovid Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView", "description": "<a href=\"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQVW5iUlNvcmVCdDdVY3hzRmRCWDR4ZnRDS0lQRjVMZDg1RnZjczV0NWprMzl1bzcxbmRBSDVrS0d4SFNIaUttTnJ5UjBZZUZCYU9qMFZaTDBDTWx6YlhJRkNtU2E2Y1JqWDNuaUU4TjctVFZLWlAwV09SaWNMMW1tVmRwM1ZTNjE3NFhYVEdJaE5EM3Bndmh2Uy1ERFZabVA2enZBcnBockREcXRBd2NlR09WWlBXVTllSFBscEJPc19WaTQ0alREemhVc3V2WDRhbG1fNE9FeTh6TC1JWWxwMHRZUkROLVFsT1E?oc=5\" target=\"_blank\">Ovid Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>", "publishedAt": "Wed, 13 Aug 2025 12:42:41 GMT"}, {"title": "Ovid Therapeutics Transfers Stock to Nasdaq Capital Market - The Globe and Mail", "description": "<a href=\"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNQnQwenRsWEVCUXdHZW03bC1MaV9XakVFbmF6TjlyR3NVQkdhcTM0akdxeEVsemo4OWN1LVQwTGpJdjNQVmM3SUVoVkVPaHBJbGlSNmhHNnUtbWlfMUZ4RHJObEVyZGtOeHRqOG1iYmxXaUUydFJhcHpnWVhBUVdRblc4bUwyNDM5QnRvSEx1OVY3TmxvczhuOURORVV0Yy1ydXhzc2lMV0cyUEptWDZkU3d4YlhsTEdxeER6WHRHUlAzWmE2aFpWcGNrUTM2MXREMGIzcVl6dWs5QXFhdUdn?oc=5\" target=\"_blank\">Ovid Therapeutics Transfers Stock to Nasdaq Capital Market</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Globe and Mail</font>", "publishedAt": "Thu, 14 Aug 2025 12:44:00 GMT"}, {"title": "Ovid Therapeutics Transfers Stock to Nasdaq Capital Market - TipRanks", "description": "<a href=\"https://news.google.com/rss/articles/CBMirwFBVV95cUxNWHFKUEtTMzZzSTVsRVA1bjlHODNFUldMcmZkX3kwazdEREZMT2ExM3NmWTdQRS1CQzQ5dUJjUmhRaG9CRkhDcGlfd3FZRXRKM3BXNmljd3ZwWlp3TnB6OUI2T1lUTFk5dnh6d2NUV1FTUnV2X1pwOTlPbHI2SHNqemhOdzQ3X1JBVVdzQnhBQVNZZWJ6S0ZzZWhnMnFZQVlzRVhGQ1RhYWlCcUFtM1pv?oc=5\" target=\"_blank\">Ovid Therapeutics Transfers Stock to Nasdaq Capital Market</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>", "publishedAt": "Wed, 13 Aug 2025 12:36:54 GMT"}, {"title": "Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - Stock Titan", "description": "<a href=\"https://news.google.com/rss/articles/CBMivgFBVV95cUxPZ1BPODJZbWt6MTdsNE8xaTBjZVJuWmJFdThxV0hHd091dWp0cFFYVkV3Q25qcU02dFNWMGRSMmdoeE1jaW9FbU9ub05LM1NQUGQ5aGw3dHZhblFlVVMyVkluZmVPdXl5d2tROElBZXlzbHZlNW1pQlg1UGhJemRpdFBsTHlkWWw0MUpBRFp5eHJoMzNKYnFqMVBfdllMekFmZFltT2lhNXg4U2UzbEd1cy0tNGpnTlVJelpYYmRR?oc=5\" target=\"_blank\">Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Stock Titan</font>", "publishedAt": "Wed, 13 Aug 2025 12:00:00 GMT"}, {"title": "Ovid Therapeutics shares rise 34.92% intraday after reporting business updates and a $7.0 million royalty monetization agreement. - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPSG03TUl3YXdlYzE5NXJUWWRkM3lscnUyZkIzNy0xZjBSbmtOcl9qdVZBbW9LMDZxb0x0MG1PdkVOamRmWnV6WXdHOFA3SVRBdzBzd0dOYmJvZy1WMllsc3lxOHQtRUhkQ1l4dmxoZGdpQ2lsUWxQRE5xVTN6MDZHQWQxeVprU01ITE8ydHMyOVBXekNCYmlTZmFMRFNqdW5rdE1tZzNhSk9zSmxrTE9UZkEteDJZRXRLSl9HVjNLcnBJUmhYYUxZTzNTb1NlenpQdXU2Zk51QjdYYUdpQ19GYThKZw?oc=5\" target=\"_blank\">Ovid Therapeutics shares rise 34.92% intraday after reporting business updates and a $7.0 million royalty monetization agreement.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Wed, 13 Aug 2025 17:30:21 GMT"}, {"title": "Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa", "description": "<a href=\"https://news.google.com/rss/articles/CBMiygFBVV95cUxNN3NRMkh4T0xiT05WZG81a2NKNXdCaGhHZUdmTWt6dGQwemtBd0hUNzJ1TnpKUkQtOVVsZXN5MHZPcGxBQWg2dWlpNTdyNEVDRVllQ2dkZEV6dlVJLU5YeVpaaEVOUG53aVBubU5PS2I3UFdSWmt4dTNPSkc0V0FDM0czRXl2YjVqaVhjRkdXckp4ZFBaYmVPdDVsMzA4bTc1SDhOc2R2eGpxT19UZWtFUTFWS0lJUlNPRzh3MExNMENMMzJ3MWNJUmlR?oc=5\" target=\"_blank\">Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating By Investing.com</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing.com South Africa</font>", "publishedAt": "Wed, 13 Aug 2025 11:52:58 GMT"}, {"title": "Ovid Therapeutics Inc. SEC 10-Q Report - TradingView", "description": "<a href=\"https://news.google.com/rss/articles/CBMioAFBVV95cUxNQXJGTkFJMTY5U3FOTFVjUVhvQ3o3SlZ6enZvT2lBZHZuM0k0OFk2TGd4azBiLVE5V1h1WTBrd3NfRkExeHQxRi00N1E4WTMxVzZhUHM1Qm1vdjlXUzNpeVpDZjF6TFRFOHVBRHIweFpNU2VFVnhDeU1IRU5NSlVNc0c4VHdfQXJGYnZwWTdkTGlvRURGUUY2S3JGdXdqVTdG?oc=5\" target=\"_blank\">Ovid Therapeutics Inc. SEC 10-Q Report</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>", "publishedAt": "Wed, 13 Aug 2025 12:13:00 GMT"}, {"title": "Ovid Therapeutics Reports Increased Revenue Amid Challenges - TipRanks", "description": "<a href=\"https://news.google.com/rss/articles/CBMisAFBVV95cUxQZ1B2UGotMWRnc2EwcmRnN29KS1lLeEpWVkdOYVlZYU1fLW1TM0JwTWRVaERsQWpUb1ZRX0M0aGowN2tieXRWNC1tNmlULVROTEM0SUlwVjlERUN6dGhrVVJxeXFNMHBsV1JTbmMtUDJ4OUdpSGhmUmtSRENHbTZWWTlBa2tMM2Z5YjJEV1FCM3FZUGprNnczOEVyUUpFUGtINzhJSTZhM2o3NkhSZWl0Vg?oc=5\" target=\"_blank\">Ovid Therapeutics Reports Increased Revenue Amid Challenges</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>", "publishedAt": "Thu, 14 Aug 2025 05:45:50 GMT"}, {"title": "Analyzing Ovid Therapeutics Inc. with risk reward ratio charts - 2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMinAFBVV95cUxQTU1fYzRkX3Voa190VER3bnQwWVRCSkxMWFM0aEtSSmZaUDlOOG1zamdldTZMRDdoM043aGtPdVg5U1BHRG5ScHVaWDdZLThqQWxnS21lYXpmVDNGY0I2M3RCU1RjQjVuT3NJeHhPSVI0S3FWZVRuWHA0WWR0Mzd5NWc3cm5DUnlGR0F0ejY1bkZ4UTN3VGJxMm5tWEY?oc=5\" target=\"_blank\">Analyzing Ovid Therapeutics Inc. with risk reward ratio charts - 2025 Winners & Losers & Safe Swing Trade Setup Alerts</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Sat, 16 Aug 2025 12:08:14 GMT"}, {"title": "How high can Ovid Therapeutics Inc. stock go - 2025 Momentum Check & Risk Adjusted Swing Trade Ideas - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMigAFBVV95cUxOV2NMcmt1ODhEM2ZfaDJfZ3BUaVAtdnNzUTBqVVBTRHlLZVo1VHlfUEVzVWFJUjdheEJJd1VnSWtjQU9hNkNjMk9keVIyeUJrWVBCZEFFMHZMY3otR01zVFIwZUJyZ0xRNXQ3WVBaWGl3N0hrQ1NQaE42UW9vcy1QcA?oc=5\" target=\"_blank\">How high can Ovid Therapeutics Inc. stock go - 2025 Momentum Check & Risk Adjusted Swing Trade Ideas</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Sat, 16 Aug 2025 11:37:19 GMT"}, {"title": "Ovid Therapeutics (NASDAQ:OVID) Trading Up 7.9% \u2013 Here\u2019s Why - Defense World", "description": "<a href=\"https://news.google.com/rss/articles/CBMinwFBVV95cUxQQzZ2aERhUGJIYlUwTk9Yc0RfOGVmVXF6clhQYXgzS09yMHJjWUxCUG1oVmMya0NZRnV4LV9ObFEyY0Vvc2tjUERlRkxqTmNDa3JJUHZXclBQUExmSDlVdzUtU3NMM0hWWVZJVE05Y1h4dFg5bGh1ME5XRk1iVExRZk84NXhxYUpjZTVRcnhhaUF2dUJ6VnVHLWlRd0VpSnc?oc=5\" target=\"_blank\">Ovid Therapeutics (NASDAQ:OVID) Trading Up 7.9% \u2013 Here\u2019s Why</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Defense World</font>", "publishedAt": "Tue, 12 Aug 2025 07:07:37 GMT"}, {"title": "Is Ovid Therapeutics Inc. stock poised for growth - Free Watchlist for Low Risk High Return - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMihAFBVV95cUxOOWFWdVlCUXZENjJEazhBZm5BcHAyNVAzVXA1N1Q2VE5qbElSenVuaTN5Wnd3UlRXb2U5Rkw4TjNmS0pSVUNnOEQ1LWQ1R05SajBmYnhNTm5zWFJvanhJbHA0ck1DUU1hZ2hMUHVIcUNiVVhHZXE1TzluM2w0WHFHRTdIRzc?oc=5\" target=\"_blank\">Is Ovid Therapeutics Inc. stock poised for growth - Free Watchlist for Low Risk High Return</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Tue, 12 Aug 2025 01:04:59 GMT"}, {"title": "Ovid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street Zen - Defense World", "description": "<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOamtGV19wWUNodk5nRHNrRGVOTktEXy10WnlQZUFDS1A0WEVjZGUwNk45MDZEazFnUHJ4SmhKUkRIbjlXNHhkYXRNWmNwQnlZMWdOc1B3RURlMjhlZ28xN0FyTk04YkRrVzBMSUR0dG1oTHJIQi1YU2pHZGxLdlhObGZabjgxbDRRZS1MRklqYlBnQTd5dk1fZERKTEo2TVFFYThXY2VUakNMMGFWZllZR2VaTGdPbk9f?oc=5\" target=\"_blank\">Ovid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street Zen</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Defense World</font>", "publishedAt": "Sat, 16 Aug 2025 06:52:45 GMT"}, {"title": "Ovid Therapeutics (NASDAQ:OVID) Given Consensus Rating of \u201cBuy\u201d by Brokerages - Defense World", "description": "<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPenFBUnBaZWtjODhGVXgtbFJUSHZrSU1NcUljUXhsYUY5MDdzSzNBOXhya1JrSjF6NkFGUExqRmtVeGhjTGpmUHc3bWp1Z1pHSGxUSkdNY1J1Y3NPYmgxZlppTDFLOG9ydEFMdHZpdk10ODA5MHZLSHVhMHFEYTAyZkcwMkNyNFJmNFJHZDRkRGd2WEx2XzUxUUtTN2tyVnlNT1BzVnc4UERmY2J0RHJ3N0h6dFVKXzVO?oc=5\" target=\"_blank\">Ovid Therapeutics (NASDAQ:OVID) Given Consensus Rating of \u201cBuy\u201d by Brokerages</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Defense World</font>", "publishedAt": "Wed, 13 Aug 2025 10:40:16 GMT"}]